Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$494M 3321.3%Beat EPS +145.9%
Total revenue, Q3 '24 ().

Did CureVac Beat Earnings?

CureVac (CVAC) reported Q3 '24 revenue of $494M, up 2,896.4% year-over-year, with reported EPS of $1.50. That topped the $0.61 analyst estimate by 145.9% — an earnings beat.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — CureVac’s job postings, web traffic, and employee business outlook. See the full CVAC stock analysis or the earnings calendar for upcoming reports.

CureVac Quarterly Financial Trends ()

MetricQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26
Revenue12M14M494M14M890,0001.2M494M—
Gross margin-236.9%-182.1%95.6%89.7%2.0%-77.8%95.8%—
Operating margin-592.6%-510.0%74.6%-283.3%-6,128.4%-4,959.5%74.6%—
Net income-71M-73M338M-33M-52M-60M338M—
Net margin-570.2%-502.5%68.4%-226.4%-5,832.5%-4,783.9%68.4%—
EPS——$1.50—————

CureVac Earnings Trend Analysis

Over the eight quarters from Q1 '24 to Q1 '26, CureVac’s quarterly revenue moved from $12M to $0. CureVac has beaten Wall Street EPS estimates in 1 of its last 1 reported quarters.

When Is CureVac’s Next Earnings Date?

CureVac reports earnings on a quarterly schedule. Its most recent report covered Q3 '24. For the confirmed upcoming date — and every other company reporting soon — see the CVAC earnings calendar.

Frequently Asked Questions: CureVac Earnings

CureVac's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

CureVac reported Q3 '24 EPS of $1.50 on revenue of $494M (+2,896.4% YoY). CureVac beat estimates, reporting $1.50 vs. the $0.61 estimate.

CureVac reported Q3 '24 revenue of $494M, up 2,896.4% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the CVAC AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.